City Therapeutics, Inc. Common Stock Asset Resilience Ratio

Latest as of June 2010: 15.16%

City Therapeutics, Inc. Common Stock asset resilience ratio. City Therapeutics, Inc. Common Stock (CTY) has an Asset Resilience Ratio of 15.16% as of June 2010. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See CTY defensive asset coverage days to measure how many days the company can operate on defensive assets alone.

Liquid Assets

$138.00 Million
Cash + Short-term Investments

Total Assets

$910.00 Million
All company assets

Resilience Assessment

Good
Financial Resilience Level

Asset Resilience Ratio of City Therapeutics, Inc. Common Stock (2006–2007)

Asset resilience ratio of City Therapeutics, Inc. Common Stock from 2006 to 2007. This chart shows how City Therapeutics, Inc. Common Stock's Asset Resilience Ratio has changed over time. Read how much debt does City Therapeutics, Inc. Common Stock carry for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down City Therapeutics, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see CTY total assets.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents $0.00 0%
Short-term Investments $138.00 Million 15.16%
Total Liquid Assets $138.00 Million 15.16%

Asset Resilience Insights

  • Good Liquidity Position: City Therapeutics, Inc. Common Stock maintains a healthy 15.16% of assets in liquid form.
  • This level provides good financial flexibility while maintaining productive asset deployment.
  • The company has significant short-term investments, indicating active treasury management.

City Therapeutics, Inc. Common Stock Industry Peers by Asset Resilience Ratio

Compare City Therapeutics, Inc. Common Stock's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 0.00%
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
Biotechnology 62.31%
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SHG:603392
Biotechnology 10.35%
Xiamen Amoytop Biotech Co Ltd
SHG:688278
Biotechnology 4.69%
SOLENO THERAPEUT. DL-001
F:6XC
Biotechnology 41.74%
89bio Inc
NASDAQ:ETNB
Biotechnology 71.60%
LegoChem Biosciences Inc
KQ:141080
Biotechnology 55.88%
DNA Link Inc
KQ:127120
Biotechnology 0.00%

City Therapeutics, Inc. Common Stock Asset Resilience Ratio by Year (2006–2007)

City Therapeutics, Inc. Common Stock asset resilience ratio by year from 2006 to 2007. The table below shows the annual Asset Resilience Ratio data for City Therapeutics, Inc. Common Stock.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2007-12-31 2.86% $20.00 Million $700.00 Million +2.57pp
2006-12-31 0.28% $42.00 Million $14.85 Billion --
pp = percentage points

About City Therapeutics, Inc. Common Stock

NASDAQ:CTY USA Biotechnology
Market Cap
$911.01 Million
Market Cap Rank
#9050 Global
#2589 in USA
Share Price
$18.10
Change (1 day)
-4.64%
52-Week Range
$16.41 - $22.14
All Time High
$22.14
About

City Therapeutics, Inc. operates as a biopharmaceutical company focused on developing RNA interference (RNAi)-based medicines by engineering RNAi trigger molecules. The company develops RNAi-based medicines using engineered small interfering RNAs (siRNAs) and is building a pipeline of therapeutics targeting diseases across multiple therapeutic areas, including ophthalmologic conditions such as re… Read more